Evidence map›Paper›PMID 32200864›Full record

ArticleKidney international2020

SGLT2i and postglomerular vasodilation.

María José Soler, Esteban Porrini, Beatriz Fernandez-Fernandez, Alberto Ortiz

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Kidney international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Primary Aldosteronism.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

María José SolerSpanish Renal Research Network, Madrid, Spain; Nephrology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Nephrology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain; Grupo Español de Estudio de la Nefropatia Diabetica (GEENDIAB), Barcelona, Spain.
Esteban PorriniSpanish Renal Research Network, Madrid, Spain; Instituto de Tecnologías Biomédicas, Hospital Universitario de Canarias, Universidad de La Laguna, Santa Cruz de Tenerife, Spain.
Beatriz Fernandez-FernandezSpanish Renal Research Network, Madrid, Spain; Department of Nephrology and Hypertension, El Instituto de Investigación Sanitaria de la Fundación Jiménez Diaz Autónoma de Madrid, Madrid, Spain; School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Alberto OrtizSpanish Renal Research Network, Madrid, Spain; Department of Nephrology and Hypertension, El Instituto de Investigación Sanitaria de la Fundación Jiménez Diaz Autónoma de Madrid, Madrid, Spain; School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain. Electronic address: aortiz@fjd.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2MetforminBenzhydryl CompoundsDouble-Blind MethodGlucosidesHumansSodium-Glucose Transporter 2VasoconstrictionVasodilationBenzhydryl CompoundsdapagliflozinGlucosidesMetforminSodium-Glucose Transporter 2

Identifiers

PMID32200864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.